Electra Therapeutics upsized its U.S. IPO to raise nearly $350M, pricing 23.3M shares at $15 each on Nasdaq under ticker ETRA. The biotech plans to use proceeds for its lead asset ipsoprubart and working capital. Jefferies, TD Cowen, Evercore ISI, and Cantor are joint book-running managers.